10 assets in Fallopian Tube Transitional Cell Carcinoma

Therapeutic assets addressing Fallopian Tube Transitional Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P3	BBB (72)
Adriamycin Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P3	BB (71)
Cediranib Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P3	BB (69)
Olaparib Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P3	BB (68)
Nogitecan Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2/3	BB (64)
Docetaxel Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P3	B (60)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Fallopian Tube Transitional Cell Carcinoma	Mayo Clinic	P2	B (59)
Durvalumab Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)